Netscape Portable Runtime

InspireMD Announces Third Quarter 2020 Financial Results

Retrieved on: 
Monday, November 9, 2020

ET

Key Points: 
  • ET
    TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR)(Inspire or the Company), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the third quarter ended September 30, 2020.
  • Third Quarter 2020 and recent highlights:
    The U.S. Food and Drug Administration (FDA) granted InspireMD approval of its Investigational Device Exemption (IDE) application to initiate a pivotal study of CGuard EPS.
  • Financial Results for the Third Quarter and Nine Months ended September 30, 2020
    For the three months ended September 30, 2020, revenue increased by $41,000, or 4.4%, to $980,000, from $939,000 during the three months ended September 30, 2019.
  • Management will host a conference call at 8:30AM ET today, November 9, 2020, to review financial results and provide an update on corporate developments.

InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12

Retrieved on: 
Tuesday, May 5, 2020

TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcast on Tuesday, May 12, 2020, to discuss financial results for the first quarter ended March 31, 2020, and provide a corporate update.

Key Points: 
  • TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that management will host a conference call and webcast on Tuesday, May 12, 2020, to discuss financial results for the first quarter ended March 31, 2020, and provide a corporate update.

InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10

Retrieved on: 
Tuesday, March 3, 2020

TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10, 2020, to discuss financial results for the fourth quarter and year ended December 31, 2019, and provide a corporate update.

Key Points: 
  • TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10, 2020, to discuss financial results for the fourth quarter and year ended December 31, 2019, and provide a corporate update.